{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:45:34Z","timestamp":1792003534404,"version":"4.4.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T00:00:00Z","timestamp":1716854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T00:00:00Z","timestamp":1716854400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The objective of our work was to evaluate the screening of hepatic fibrosis in primary care using the FIB-4 score, automatically calculated. When the FIB-4 was\u2009\u2265\u20091.3, it was defined as positive, and ELF Test was performed. FIB-4 positivity was confirmed when ELF Test was\u2009\u2265\u20099.8 indicating an advanced fibrosis. Among the 3427 patients included, 869 (25%) had a positive FIB-4 score, 784 (22.5%) at intermediate (FIB-4: 1.3\u20132.67), and 85 (2.5%) at high risk of fibrosis (FIB-4\u2009&gt;\u20092.67). 509 (59%) of the FIB-4 positive were confirmed by the ELF Test. The percentage of confirmation was significantly higher in patients over 65 years (83 vs. 57%), with FIB-4\u2009&gt;\u20092.67 (80 vs. 56%), BMI\u2009&gt;\u200925 (47 vs. 37%), and diabetes (24 vs. 14%), p\u2009=\u20090.001). In patients without known liver disease (92%), the practitioner identified a cause of disease in 27% of cases: mainly NAFLD and alcohol. Liver fibrosis was suspected on FIB-4 in 25% of patients in primary care. The ELF Test, performed as a second-line, improves the screening of liver fibrosis, particularly for FIB-4 intermediate results. A positive FIB-4 test allows physicians to recognize a liver disease, providing an opportunity for timely intervention.<\/jats:p>\n                  <jats:p>\n                    <jats:bold>Clinical trial registration<\/jats:bold>\n                    : Comit\u00e9 de protection des personnes du sud-ouest et outre-mer SI18.00832.201865-MS04-IDRCB 2018-A01571-54.\n                  <\/jats:p>","DOI":"10.1038\/s41598-024-62549-3","type":"journal-article","created":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T15:01:45Z","timestamp":1716908505000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Using the FIB-4, automatically calculated, followed by the ELF test in second line to screen primary care patients for liver disease"],"prefix":"10.1038","volume":"14","author":[{"given":"Denis","family":"Ouzan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Penaranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Jlaiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Joly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Corneille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,28]]},"reference":[{"key":"62549_CR1","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jhep.2018.09.014","volume":"70","author":"SK Asrani","year":"2019","unstructured":"Asrani, S. K., Devarbhavi, H., Eaton, J. & Kamath, P. S. Burden of liver diseases in the world. J. Hepatol. 70, 151\u2013171 (2019).","journal-title":"J. Hepatol."},{"key":"62549_CR2","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi, Z. M. et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64, 73\u201384 (2016).","journal-title":"Hepatology"},{"key":"62549_CR3","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.jhep.2015.03.025","volume":"63","author":"European Association for Study of Liver","year":"2015","unstructured":"European Association for Study of Liver. EASL recommendations on treatment of hepatitis C 2015. J. Hepatol. 63, 199\u2013236 (2015).","journal-title":"J. Hepatol."},{"key":"62549_CR4","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/hep.28156","volume":"63","author":"NA Terrault","year":"2016","unstructured":"Terrault, N. A. et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology 63, 261\u2013283 (2016).","journal-title":"Hepatology"},{"key":"62549_CR5","first-page":"1388","volume":"2016","author":"EASL","year":"2016","unstructured":"EASL. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J. Hepatol. 2016, 1388\u20131402 (2016).","journal-title":"J. Hepatol."},{"key":"62549_CR6","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1210\/jc.2006-0075","volume":"91","author":"N Chalasani","year":"2006","unstructured":"Chalasani, N., Vuppalanchi, R., Raikwar, N. S. & Deeg, M. A. Glycosylphosphatidylinositol-specific phospholipase d in nonalcoholic Fatty liver disease: A preliminary study. J. Clin. Endocrinol. Metab. 91, 2279\u20132285 (2006).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"62549_CR7","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.jhep.2015.04.006","volume":"63","author":"European Association for Study of Liver","year":"2015","unstructured":"European Association for Study of Liver, Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J. Hepatol. 63, 237\u2013264 (2015).","journal-title":"J. Hepatol."},{"key":"62549_CR8","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/S0140-6736(00)04258-6","volume":"357","author":"F Imbert-Bismut","year":"2001","unstructured":"Imbert-Bismut, F. et al. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: A prospective study. The Lancet 357, 1069\u20131075 (2001).","journal-title":"The Lancet"},{"key":"62549_CR9","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1002\/hep.20935","volume":"42","author":"P Cales","year":"2005","unstructured":"Cales, P. et al. A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology 42, 1373\u20131381 (2005).","journal-title":"Hepatology"},{"key":"62549_CR10","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1373\/jalm.2018.027359","volume":"3","author":"J Day","year":"2019","unstructured":"Day, J., Patel, P., Parkes, J. & Rosenberg, W. Derivation and performance of standardized enhanced liver fibrosis (ELF) test thresholds for the detection and prognosis of liver fibrosis. J. Appl. Lab. Med. 3, 815\u2013826 (2019).","journal-title":"J. Appl. Lab. Med."},{"key":"62549_CR11","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1016\/j.clinbiochem.2010.08.010","volume":"43","author":"P Cal\u00e8s","year":"2010","unstructured":"Cal\u00e8s, P. et al. Optimization and robustness of blood tests for liver fibrosis and cirrhosis. Clin. Biochem. 43, 1315\u20131322 (2010).","journal-title":"Clin. Biochem."},{"key":"62549_CR12","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1002\/hep.21178","volume":"43","author":"RK Sterling","year":"2006","unstructured":"Sterling, R. K. et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection. Hepatology 43, 1317\u20131325 (2006).","journal-title":"Hepatology"},{"key":"62549_CR13","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1053\/jhep.2003.50346","volume":"38","author":"C-T Wai","year":"2003","unstructured":"Wai, C.-T. et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 38, 518\u2013526 (2003).","journal-title":"Hepatology"},{"key":"62549_CR14","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1002\/hep.21496","volume":"45","author":"P Angulo","year":"2007","unstructured":"Angulo, P. et al. The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 45, 846\u2013854 (2007).","journal-title":"Hepatology"},{"key":"62549_CR15","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1002\/hep.29302","volume":"66","author":"G Xiao","year":"2017","unstructured":"Xiao, G. et al. Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: A meta-analysis. Hepatology 66, 1486\u20131501 (2017).","journal-title":"Hepatology"},{"key":"62549_CR16","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/j.cgh.2009.05.033","volume":"7","author":"AG Shah","year":"2009","unstructured":"Shah, A. G. et al. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 7, 1104\u20131112 (2009).","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"75","key":"62549_CR17","first-page":"659","volume":"2021","author":"European Association for the Study of the Liver","year":"2021","unstructured":"European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, Clinical Practice Guideline Panel, Chair:, EASL Governing Board representative:, Panel members: EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis\u20142021 update. J. Hepatol. 2021(75), 659\u2013689 (2021).","journal-title":"J. Hepatol."},{"key":"62549_CR18","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1111\/liv.15295","volume":"43","author":"AD Schreiner","year":"2023","unstructured":"Schreiner, A. D. et al. FIB-4 and incident severe liver outcomes in patients with undiagnosed chronic liver disease: A Fine-Gray competing risk analysis. Liver Int. 43, 170\u2013179 (2023).","journal-title":"Liver Int."},{"key":"62549_CR19","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1002\/hep.29113","volume":"66","author":"A Unalp-Arida","year":"2017","unstructured":"Unalp-Arida, A. & Ruhl, C. E. Liver fibrosis scores predict liver disease mortality in the United States population. Hepatology 66, 84\u201395 (2017).","journal-title":"Hepatology"},{"key":"62549_CR20","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1097\/HEP.0000000000000323","volume":"77","author":"ME Rinella","year":"2023","unstructured":"Rinella, M. E. et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology 77, 1798\u20131835 (2023).","journal-title":"Hepatology"},{"key":"62549_CR21","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.jhep.2019.03.033","volume":"71","author":"A Srivastava","year":"2019","unstructured":"Srivastava, A. et al. Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease. J. Hepatol. 71, 371\u2013378 (2019).","journal-title":"J. Hepatol."},{"key":"62549_CR22","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.jhep.2023.04.002","volume":"79","author":"M Kjaergaard","year":"2023","unstructured":"Kjaergaard, M. et al. The ELF test, FIB-4 and NAFLD fibrosis score to screen the population for liver disease. J. Hepatol. 79, 279\u2013286 (2023).","journal-title":"J. Hepatol."},{"key":"62549_CR23","doi-asserted-by":"publisher","first-page":"e986","DOI":"10.1097\/MEG.0000000000002340","volume":"33","author":"D Ouzan","year":"2021","unstructured":"Ouzan, D. et al. Prospective screening for significant liver fibrosis by fibrosis-4 in primary care patients without known liver disease. Eur. J. Gastroenterol. Hepatol. 33, e986\u2013e991 (2021).","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"62549_CR24","doi-asserted-by":"publisher","first-page":"101848","DOI":"10.1016\/j.clinre.2021.101848","volume":"46","author":"CM Canivet","year":"2022","unstructured":"Canivet, C. M. et al. Awareness of chronic liver diseases, a comparison between diabetologists and general practitioners. Clin. Res. Hepatol. Gastroenterol. 46, 101848 (2022).","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"62549_CR25","doi-asserted-by":"publisher","first-page":"e0254939","DOI":"10.1371\/journal.pone.0254939","volume":"16","author":"P Halfon","year":"2021","unstructured":"Halfon, P. et al. Prospective screening of liver fibrosis in a primary care cohort using systematic calculation of fib-4 in routine results. PLoS One 16, e0254939 (2021).","journal-title":"PLoS One"},{"key":"62549_CR26","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.1016\/S0168-8278(20)30595-X","volume":"73","author":"A Yeoman","year":"2020","unstructured":"Yeoman, A. et al. Introduction of \u201creflex\u201d AST testing in primary care increases detection of advanced liver disease: The Gwent AST project (GAP). J. Hepatol. 73, S19 (2020).","journal-title":"J. Hepatol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-62549-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-62549-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-62549-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T15:11:47Z","timestamp":1716909107000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-62549-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,28]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["62549"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-62549-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3739951\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,28]]},"assertion":[{"value":"11 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12198"}}